Written on Monday 12th October 2020
Potential Therapeutic Roles for IBAT Inhibitors in Cholestatic and Metabolic Liver Diseases
Independent symposium chaired by Dr Saul Karpen
With Dr Paul Dawson, Dr Kathleen Loomes, and Dr Arun Sanyal
Sunday November 15TH 2020 | 19:00 – 21:00 EST
Presentations
Audience
Learning objectives
After attending this symposium, learners will be able to:
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Liberum IME. ACHL is accredited by the ACCME to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Presented for attendees of The Liver Meeting Digital Experience™. This event is sponsored by Liberum IME and supported by Albireo Pharmaceuticals. This is not an official event of the American Association for the Study of Liver Diseases.